Welcome to our dedicated page for Imac Hldgs SEC filings (Ticker: BACK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IMAC Holdings, Inc. (BACK) files a range of documents with the U.S. Securities and Exchange Commission that shed light on its precision oncology strategy, financing structure, and reporting status. As a public company with SEC file number 001‑38797 and CUSIP 44967K302, IMAC uses its filings to describe material agreements, debt obligations, and timing of periodic reports.
Recent Form 8‑K reports detail multiple promissory notes and a Securities Purchase Agreement for senior secured notes. These filings outline original principal amounts, purchase prices, maturities, security interests, and customary events of default, including bankruptcy or insolvency events. One 8‑K describes a Security and Pledge Agreement granting a first‑priority security interest in substantially all assets of IMAC and certain subsidiaries, including Ignite Proteomics LLC and several healthcare‑related entities, as collateral for senior secured notes.
IMAC’s filings also include a Form 12b‑25 (NT 10‑Q) explaining delays in filing its Quarterly Report on Form 10‑Q for the period ended September 30, 2025. In that notification, the company cites delays in compiling financial and other information and states its intention to file within the allowed extension period. Separate Nasdaq notices referenced in company news discuss deficiency letters and exceptions related to timely filing requirements, which are closely tied to the information in IMAC’s periodic reports.
On this SEC filings page, users can review IMAC’s 8‑Ks on new debt arrangements, security agreements, and guaranties, as well as late‑filing notifications and other disclosures. Stock Titan’s tools can surface key elements from lengthy documents—such as the scope of collateral, identities of guarantor subsidiaries, or the nature of reporting delays—helping readers understand how IMAC structures its obligations and how its regulatory reporting aligns with its evolving precision oncology business through Ignite Proteomics.
IMAC Holdings, Inc. (ticker: BACK) filed an 8-K on 17 Jun 2025 disclosing a new promissory note. The company issued an unsecured note with an aggregate principal of $301,000 in exchange for $215,000 cash proceeds from a single lender, implying a substantial original-issue discount. The note carries a short maturity date of 24 Dec 2025—about six months—suggesting near-term repayment pressure. Management can prepay at any time without penalty, which provides financial flexibility. Standard representations, covenants and bankruptcy-related default triggers apply; upon default, the lender may accelerate repayment. No collateral, equity conversion features, or warrants were disclosed, and the instrument references the form of note previously filed on 6 May 2025 (Exhibit 4.1).
Key implications for investors:
- The additional borrowing modestly increases leverage for this micro-cap company, though the absolute dollar amount is small.
- The unsecured structure avoids encumbering assets, but the discount (≈29% between principal and cash received) indicates a high effective cost of capital.
- Management’s ability to prepay without penalty could reduce interest expense if cash flow permits early retirement.
- The short tenor concentrates refinancing/repayment risk into the next two quarters, making future liquidity updates important.
No other material agreements, financial statements, or earnings data accompanied the filing.